Linscomb & Williams Inc. Acquires 88 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Linscomb & Williams Inc. raised its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.9% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 4,657 shares of the medical research company’s stock after purchasing an additional 88 shares during the period. Linscomb & Williams Inc.’s holdings in Thermo Fisher Scientific were worth $2,126,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in TMO. Fort Washington Investment Advisors Inc. OH increased its stake in shares of Thermo Fisher Scientific by 14.1% during the fourth quarter. Fort Washington Investment Advisors Inc. OH now owns 2,830 shares of the medical research company’s stock valued at $1,318,000 after purchasing an additional 350 shares in the last quarter. Bailard Inc. increased its position in shares of Thermo Fisher Scientific by 27.5% during the fourth quarter. Bailard Inc. now owns 947 shares of the medical research company’s stock valued at $441,000 after acquiring an additional 204 shares in the last quarter. Cambridge Investment Research Advisors Inc. increased its position in shares of Thermo Fisher Scientific by 9.3% during the fourth quarter. Cambridge Investment Research Advisors Inc. now owns 41,104 shares of the medical research company’s stock valued at $19,146,000 after acquiring an additional 3,494 shares in the last quarter. Steel Peak Wealth Management LLC bought a new stake in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $535,000. Finally, Daiwa Securities Group Inc. increased its position in shares of Thermo Fisher Scientific by 1.0% during the fourth quarter. Daiwa Securities Group Inc. now owns 21,849 shares of the medical research company’s stock valued at $10,177,000 after acquiring an additional 208 shares in the last quarter. 86.03% of the stock is owned by institutional investors and hedge funds.

TMO opened at $464.91 on Friday. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.91 and a current ratio of 2.53. Thermo Fisher Scientific Inc. has a fifty-two week low of $330.57 and a fifty-two week high of $532.57. The company’s fifty day moving average price is $467.53. The stock has a market cap of $182.72 billion, a PE ratio of 23.41, a price-to-earnings-growth ratio of 1.08 and a beta of 0.76.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Thursday, April 29th. The medical research company reported $7.21 earnings per share for the quarter, beating analysts’ consensus estimates of $6.69 by $0.52. Thermo Fisher Scientific had a net margin of 22.08% and a return on equity of 28.95%. The company had revenue of $9.91 billion for the quarter, compared to analysts’ expectations of $9.69 billion. Thermo Fisher Scientific’s revenue for the quarter was up 59.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.94 EPS. On average, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 22 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, July 15th. Shareholders of record on Tuesday, June 15th will be issued a $0.26 dividend. The ex-dividend date of this dividend is Monday, June 14th. This represents a $1.04 dividend on an annualized basis and a yield of 0.22%. Thermo Fisher Scientific’s dividend payout ratio is currently 5.32%.

Several brokerages recently weighed in on TMO. Evercore ISI raised their price target on shares of Thermo Fisher Scientific from $525.00 to $540.00 and gave the company an “outperform” rating in a research report on Friday, April 16th. Barclays began coverage on shares of Thermo Fisher Scientific in a report on Monday, March 8th. They issued an “overweight” rating and a $525.00 target price on the stock. KeyCorp upgraded shares of Thermo Fisher Scientific from a “sector weight” rating to an “overweight” rating and set a $520.00 target price on the stock in a report on Thursday, March 18th. Robert W. Baird restated a “buy” rating on shares of Thermo Fisher Scientific in a report on Monday, May 3rd. Finally, UBS Group dropped their target price on shares of Thermo Fisher Scientific from $588.00 to $560.00 and set a “buy” rating on the stock in a report on Monday, March 29th. Three equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $534.45.

In other Thermo Fisher Scientific news, EVP Michel Lagarde sold 34,168 shares of Thermo Fisher Scientific stock in a transaction on Friday, May 7th. The shares were sold at an average price of $472.60, for a total value of $16,147,796.80. Following the sale, the executive vice president now directly owns 52,629 shares in the company, valued at approximately $24,872,465.40. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.44% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Read More: Environmental, Social, and Governance (ESG) Investing

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.